Skip to content


  • Poster presentation
  • Open Access

Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance

  • 1,
  • 2,
  • 2,
  • 2,
  • 3,
  • 3,
  • 1,
  • 3,
  • 2,
  • 3,
  • 2 and
  • 2
Journal for ImmunoTherapy of Cancer20153 (Suppl 2) :P39

  • Published:


  • Tumor Microenvironment
  • Tumor Regression
  • Durable Regression
  • Proteasomal Degradation
  • Cancer Immunotherapy


Improving the functional avidity of effector T cells is critical in overcoming inhibitory factors within the tumor microenvironment and eliciting tumor regression.


We have found that Cish, a member of the Suppressor of Cytokine Signaling (SOCS) family, is induced by TCR stimulation in CD8+ T cells and inhibits their functional avidity against tumor.


Genetic deletion of Cish in CD8+ T cells enhances their expansion, functional avidity and cytokine polyfunctionality, resulting in pronounced and durable regression of established tumors. Although Cish is commonly thought to block STAT5 activation, we found that the primary molecular basis of Cish suppression is through inhibition of TCR signaling. Cish physically interacts with the TCR intermediate PLCg1, targeting it for proteasomal degradation following TCR stimulation. Furthermore we extend these findings to patients PBL retrovirally transduced with tumor-specific TCRs and shorthairpin microRNAs targeting CISH.


These findings establish a novel targetable interaction that regulates the functional avidity of tumor-specific CD8+ T cells and can be manipulated to improve adoptive cancer immunotherapy.

Authors’ Affiliations

NIH/NCI - Surgery Branch, Bethesda, MD, USA
NCI, Bethesda, MD, USA
Center for Cancer Research, NCI/NIH, Bethesda, MD, USA